Cat. No.: HY-13304

LY2874455

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

LY2874455 is a pan-FGFR inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.14%
CAS No.: 1254473-64-7
Formule: C₂₁H₁₉Cl₂N₅O₂
Masse moléculaire:444.31

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

LY2874455 Chemical Structure

CAS No.: 1254473-64-7

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

LY2874455 is a pan-FGFR inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

IC₅₀ & Target^[1]

FGFR1

2.8 nM (IC₅₀)

FGFR2

2.6 nM (IC₅₀)

FGFR3

6.4 nM (IC₅₀)

FGFR4

6 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.099 μM Compound: 4; LY2874455	Antiproliferative activity against human A2780 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]
AN3-CA	IC₅₀	6.613 nM Compound: 4; LY2874455	Antiproliferative activity against human AN3-CA cells overexpressing FGFR2 measured after 72 hrs by MTT assay Antiproliferative activity against human AN3-CA cells overexpressing FGFR2 measured after 72 hrs by MTT assay	[PMID: 38908103]
BaF3	IC₅₀	0.001 μM Compound: 5; LY2874455	Antiproliferative activity against mouse BAF3 cells expressing wild-type FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against mouse BAF3 cells expressing wild-type FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 35271262]
BaF3	IC₅₀	0.007 μM Compound: LY2874455	Antiproliferative activity against mouse BaF3 cells harbouring ETV6-FGFR4-V550L mutant measured after 24 to 48 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring ETV6-FGFR4-V550L mutant measured after 24 to 48 hrs by MTT assay	[PMID: 37437349]
BaF3	IC₅₀	0.171 μM Compound: LY2874455	Antiproliferative activity against mouse BaF3 cells harbouring ETV6-FGFR4-N535K mutant measured after 24 to 48 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring ETV6-FGFR4-N535K mutant measured after 24 to 48 hrs by MTT assay	[PMID: 37437349]
BaF3	IC₅₀	340.6 nM Compound: LY2874455	Antiproliferative activity against mouse BaF3 cells expressing TEL-FGFR4 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells expressing TEL-FGFR4 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 35635004]
BXPC-3	IC₅₀	0.5 μM Compound: 4; LY2874455	Antiproliferative activity against human BXPC-3 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human BXPC-3 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]
HCT-116	IC₅₀	0.725 μM Compound: 4; LY2874455	Antiproliferative activity against human HCT-116 cells expressing FGFR1/4 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells expressing FGFR1/4 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]
HEK-293T	IC₅₀	0.547 μM Compound: 4; LY2874455	Cytotoxicity against HEK293T cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 38908103]
Hep 3B2	IC₅₀	0.001 μM Compound: 5; LY2874455	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 35271262]
Hep 3B2	IC₅₀	260.8 nM Compound: LY2874455	Antiproliferative activity against human Hep3B cells expressing FGF19/FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells expressing FGF19/FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35635004]
L02	IC₅₀	>5 μM Compound: 4; LY2874455	Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 38908103]
MCF7	IC₅₀	0.829 μM Compound: 4; LY2874455	Antiproliferative activity against human MCF7 cells expressing FGFR3 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing FGFR3 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]
MDA-MB-231	IC₅₀	1.253 μM Compound: 4; LY2874455	Antiproliferative activity against human MDA-MB-231 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells expressing FGFR1 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]
MDA-MB-453	IC₅₀	0.005 μM Compound: 5; LY2874455	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 35271262]
NCI-H1299	IC₅₀	0.059 μM Compound: 5; LY2874455	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 35271262]
NCI-H1581	IC₅₀	<0.5 nM Compound: 7	Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay	[PMID: 27348537]
NCI-H1581	IC₅₀	30.5 nM Compound: LY2874455	Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 35635004]
NCI-H1975	IC₅₀	1.353 μM Compound: 4; LY2874455	Antiproliferative activity against EGFR-driven human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against EGFR-driven human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 38908103]
RT-112	IC₅₀	8.6 nM Compound: LY2874455	Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 35635004]
SNU-16	IC₅₀	0.511 nM Compound: 4; LY2874455	Antiproliferative activity against FGFR2 amplified human SNU-16 cells measured after 72 hrs by MTT assay Antiproliferative activity against FGFR2 amplified human SNU-16 cells measured after 72 hrs by MTT assay	[PMID: 38908103]
SNU-16	IC₅₀	2.2 nM Compound: LY2874455	Antiproliferative activity against human SNU-16 cells expressing FGFR2 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human SNU-16 cells expressing FGFR2 assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 35635004]
SNU-449	IC₅₀	0.392 nM Compound: 4; LY2874455	Antiproliferative activity against human SNU-449 cells expressing FGFR1/4 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SNU-449 cells expressing FGFR1/4 assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 38908103]

In Vitro

LY2874455 potently inhibits the Erk phosphorylation induced by FGF2 and FGF9 in both cell lines in a dose-dependent manner, with average IC₅₀ values of 0.3 to 0.8 nM. LY2874455 indeed inhibits FGFR2 phosphorylation in SNU-16 and KATO-III cells, with estimated IC₅₀ values of 0.8 and 1.5 nM, respectively. In addition, LY2874455 inhibits the phosphorylation of FRS2, an immediate downstream target of FGFR in these cell lines, again with a similar potency of 0.8 to 1.5 nM. Together, these results suggest that LY2874455 inhibits FGFR in the cell. The relative IC₅₀ values of LY2874455 for KMS-11, OPM-2, L-363, and U266 cells are determined to be 0.57, 1.0, 60.4, and 290.7 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LY2874455 exhibits a rapid, robust, dose-dependent inhibition of tumor growth in all 4 models tested. Importantly, this molecule causes a significant regression of tumor growth in the RT-112, SNU-16, and OPM-2 tumor models, especially when dosed at 3 mg/kg twice a day. Also, LY2874455 exhibits an excellent pharmacokinetic/pharmacodynamic relationship as shown by its dose-dependent inhibition of the tumor growth at TED₅₀ and TED₉₀ (1 and 3 mg/kg, respectively). When tested in the RT-112 tumor xenograft model on an intermittent dosing schedule (twice a day 1 week on and 1 week off or twice a day 2 days on and 2 days off), LY2874455 is also efficacious. When rats are dosed with LY2874455 at 1 and 3 mg/kg, which is 2.6- and 7.7-fold over the TED₅₀ (0.39 mg/kg) obtained in the rat heart IVTI assay, respectively, there are no significant changes observed in blood pressure. However, when rats are dosed with LY2874455 at 10 mg/kg, which is 25.6-fold over the TED₅₀, there are significant increases observed in arterial pressures^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1254473-64-7
Appearance Solid
Masse moléculaire 444.31
Formule C₂₁H₁₉Cl₂N₅O₂
Color Off-white to pink
SMILES

ClC1=CN=CC(Cl)=C1[C@@H](C)OC2=CC=C(NN=C3/C=C/C4=CN(CCO)N=C4)C3=C2
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Open Biol

Formyl-peptide receptor 2 signalling triggers aerobic metabolism of glucose through Nox2-dependent modulation of pyruvate dehydrogenase activity. [Abstract]

2023 Oct;13(10):230336. PMID: 37875162
University of Auckland

2025.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (112.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2507 mL

11.2534 mL

22.5068 mL

5 mM

0.4501 mL

2.2507 mL

4.5014 mL

10 mM

0.2251 mL

1.1253 mL

2.2507 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.63 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.63 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

Reaction mixtures contained 8 mM Tris-HCl (pH 7.5), 10 mM HEPES, 5 mM dithiothreitol, 10 μM ATP, 0.5 μCi ³³P-ATP, 10 mM MnCl₂, 150 mM NaCl, 0.01% Triton X-100, 4% DMSO, 0.05 mg/mL poly(Glu:Tyr) (4:1, average molecular weight of 20-50 kDa), and 7.5, 7.5, and 16 ng of FGFR1, FGFR3, and FGFR4, respectively, and are incubated at room temperature for 30 minutes followed by termination with 10% H₃PO₄. The reaction mixtures are transferred to 96-well MAFB filter plates that are washed 3 times with 0.5% H₃PO₄. After air-drying, the plates are read with a Trilux reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

The different multiple myeloma cancer cell lines KMS-11 and OPM-2 cells, L-363, and U266 cells are used. Cells (2,000 per well) are first grown in RPMI for 6 hours and treated with LY2874455 at 37°C for 3 days. The cells are stained at 37°C for 4 hours and then solubilized at 37°C for 1 hour. Finally, the plate is read at 570 nm using a plate reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
RT-112, OPM-2 (DSMZ), SNU-16, and NCI-H460 cells (RT-112: 2×10⁶ per animal; OPM-2: 10⁷ per animal; SNU-16: 10⁶ per animal; and NCI-H460: 3×10⁶ per animal) are mixed with Matrigel (1:1) and implanted subcutaneously into the rear flank of the mice (female, CD-1 nu/nu for RT-112, OPM-2, and NCI-H460 cells and female, severe combined immunodeficient for SNU-16 cells). The implanted tumor cells grow as solid tumors. To test the efficacy of LY2874455 in these models, the animals are orally dosed with approximately 1 mg/kg (TED₅₀) or 3 mg/kg (TED₉₀) of LY2874455 in 10% Acacia once (every day) or twice a day after tumors reach approximately 150 mm³. The tumor volume and body weight are measured twice a week.
Rats^[1]
Four male rats per group are dosed with vehicle (1% hydroxyethylcellulose, 0.25% polysorbate 80, and 0.05% Dow Corning antifoam 1510-US in purified water) on day 1 and LY2874455 (1, 3, and 10 mg/kg) on day 0. On day 1, at least 120 minutes of control data are collected following vehicle administration. On day 0, data are collected for approximately 20 hours beginning after the last animal is dosed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhao G, et al. A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models. Molecular Cancer Therapeutics (2011), 10(11), 2200-2210. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2507 mL	11.2534 mL	22.5068 mL	56.2670 mL
	5 mM	0.4501 mL	2.2507 mL	4.5014 mL	11.2534 mL
	10 mM	0.2251 mL	1.1253 mL	2.2507 mL	5.6267 mL
	15 mM	0.1500 mL	0.7502 mL	1.5005 mL	3.7511 mL
	20 mM	0.1125 mL	0.5627 mL	1.1253 mL	2.8134 mL
	25 mM	0.0900 mL	0.4501 mL	0.9003 mL	2.2507 mL
	30 mM	0.0750 mL	0.3751 mL	0.7502 mL	1.8756 mL
	40 mM	0.0563 mL	0.2813 mL	0.5627 mL	1.4067 mL
	50 mM	0.0450 mL	0.2251 mL	0.4501 mL	1.1253 mL
	60 mM	0.0375 mL	0.1876 mL	0.3751 mL	0.9378 mL
	80 mM	0.0281 mL	0.1407 mL	0.2813 mL	0.7033 mL
	100 mM	0.0225 mL	0.1125 mL	0.2251 mL	0.5627 mL

Keywords

LY2874455

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

LY2874455

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LY2874455

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LY2874455

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) LY2874455

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LY2874455 Related Classifications

Cat. No.: HY-13304